VANCOUVER, British Columbia–(BUSINESS WIRE)–SOLVE FSHD, a venture-philanthropy organization dedicated to accelerating therapies for facioscapulohumeral muscular dystrophy (FSHD), today celebrated the closing of a US$37 million Series A financing by portfolio company Altay Therapeutics, Inc. The financing was co-led by Sound Bioventures and HealthCap, with participation from Fountain Healthcare Partners, Biogen New Ventures, Pappas Capital and Global BioAccess Fund. Altay intends to use the pr